Patrick J. Flynn

Abbott Northwestern Hospital — United States

Medicine · Health Sciences

61h-index18.9kcitations198works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(37), Colorectal Cancer Treatments and Studies(35), Glioma Diagnosis and Treatment(24), Estrogen and related hormone effects(20), HER2/EGFR in Cancer Research(16)

Publications195 total

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
The Oncologist·2025Open Access
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
2024Open Access
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Clinical Cancer Research·2024· 5 citedOpen Access
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Journal of Clinical Oncology·2024· 20 citedOpen Access
Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023Open Access
Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023Open Access
Supplementary Table 2 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Kurt A. Jaeckle(9), Kendrith M. Rowland(7), Charles L. Loprinzi(7), Caterina Giannini(7), Gary R. Morrow(7), Al B. Benson(6), Jan C. Buckner(6), Mark R. Somerfield(5), Nicholas J. Petrelli(5), James N. Atkins(5), Louis Fehrenbacher(5), Jeffrey J. Kirshner(5), Norman Wolmark(4), Sandra M. Swain(4), Shaker R. Dakhil(4), Bruce D. Minsky(4), Vera J. Suman(4), Robert B. Jenkins(4), Evanthia Galanis(4), Joseph A. Roscoe(4)